



(51) International Patent Classification:

A61K 47/68 (2017.01) *A61P 43/00* (2006.01)*C07K 16/28* (2006.01)

(21) International Application Number:

PCT/IB2017/058159

(22) International Filing Date:

19 December 2017 (19.12.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/437,622 21 December 2016 (21.12.2016) US

62/520,854 16 June 2017 (16.06.2017) US

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35,
4056 Basel (CH).

(72) **Inventors:** **WEN, Ben**; c/o Novartis Institute for Functional Genomics, Inc., dba Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, CA 92121 (US). **BOITANO, Anthony E.**; 13037 Cavalry Court, San Diego, CA 92129 (US). **BURGER, Matthew**; c/o Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139 (US). **CELLITI, Susan E.**; c/o Novartis Institute for Functional Genomics, Inc., dba Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, CA 92121 (US). **COOKE, Michael P.**; 135 University Avenue, #1, Brookline, MA 02445 (US). **FINNER, Catrin**; c/o Morphosys AG, Semmelweisstrasse 7, 82152 Planegg (DE). **GEIERSTANGER, Bernhard Hubert**; c/o Novartis Institute for Functional Genomics, Inc., dba Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, CA 92121 (US).

10675 John Jay Hopkins Drive, San Diego, CA 92121 (US). **JIN, Yunho**; c/o Novartis Institute for Functional Genomics, Inc., dba Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, CA 92121 (US). **LEE-HOEFLICH, Si Tuen**; c/o Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139 (US). **PHAM, HongNgoc Thi**; c/o Novartis Institute for Functional Genomics, Inc., dba Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, CA 92121 (US). **SCHLEYER, Siew Ho**; 2649 Monte Vista Avenue, El Cerrito, CA 94530 (US). **TISSOT, Kathrin**; c/o Morphosys AG, Semmelweisstrasse 7, 82152 Planegg (DE). **UNO, Tetsuo**; c/o Novartis Institute for Functional Genomics, Inc., dba Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, CA 92121 (US).

(74) **Agent:** **NOVARTIS AG**; Lichtstrasse 35, 4056 Basel (CH).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH,

(54) **Title:** ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS

FIG. 11A





FIG. 11B



(57) **Abstract:** The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoietic stem cells in a patient in need thereof.

[Continued on next page]

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the identity of the inventor (Rule 4.17(i))*
- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*